<table>
<thead>
<tr>
<th>Agenda Item</th>
<th>Desired Outcome</th>
</tr>
</thead>
</table>
| Welcome     | - Roll call, all Committee members present  
- Agenda review and approval  
**Motion to approve agenda was made and unanimously carried (Motion by Helm, second by Chinn).**  
- 5.29.2019 Minutes review and approval  
**Motion to approve 5/29/19 Minutes was made and unanimously carried (Motion by Chinn, second by Jones).** |
| Committee Business (times are approximate) | - High Priority Items – none  
- Committee Protocol Development –  
  - NRT and Non-NRT Smoking Cessation  
  - Pharmacist Consultant Fiona Karbowicz introduced the subject matter experts to the Committee and provided background information related to the NRT and Non-NRT Smoking Cessation concept.  
    - SMEs: Kiyomi Lehman – phone, Jennifer Davis, Sharon Rask – present  
    - SMEs: Julie Himstreet, Laura Borgelt – not present  
    - October 2018 meeting motion: RPH may prescribe individual or multiple NRT, OTC/Rx, for smoking cessation  
    - January 2019 meeting minutes included details related to the creation of a standardized patient assessment process and treatment care plan for smoking cessation/prescribing of varenicline and bupropion. At that time, the Committee recommended a motion to include a number of patient safety elements, including the utilization of a standardized questionnaire with specific questions about mental health and suicide to assist with the pharmacist’s assessment and referrals. Also included specific inclusion criteria, such as ≥ age 18, prescribing limitations, mandated follow-up parameters, and a minimum education requirement of 2 hours CE.  
    - Committee began work on finalizing the standardized questionnaire, with the assistance of SME Lehman. They determined that the questionnaire should be utilized |
for all patients seeking tobacco cessation services, and therefore asked that it be edited to flow from NRT to non-NRT questions. They requested it be designed with a pharmacist reference guide to indicate clear referral points and cautionary information to assist with product selection and counseling.

- This concept, with finalized documents will be reviewed again at the next meeting, scheduled for October 25, 2019.

- **Pre-Travel Consult Medications**

- Fiona introduced the subject matter experts to the Committee and provided background information related to travel medications.

- SMEs: Kayla Hensley, Steve Nzele, Kaylie Yoon and Jennifer Davis – present

- January 2019 meeting minute highlights include:
  - Link to the CDC’s Health Information for International Travel, aka the Yellow Book, was provided for background.
  - The Committee discussed that a substantial amount of education would be needed for a pharmacist to prescribe in these circumstances and that ongoing education would be necessary. Committee’s motion recommended: completion of APhA immunization training or equivalent, plus 4 hour travel vaccination class or equivalent; and 1 hour travel medication related CE every 2 years.
  - This would be a valuable service in rural areas where travel services are not generally available.
  - The Committee stated that assessment regarding vaccination should be conducted at this time also.

- Motion to recommend addition of the four categories of Preventative Travel Medications including:
  - Malaria Prophylaxis (chloroquine, atovaquone/proguanil, mefloquine, doxycycline);
  - Traveler's Diarrhea Prevention and Treatment (ciprofloxacin, azithromycin);
  - Acute Mountain Sickness Prophylaxis (acetazolamide); and
  - Motion Sickness (Scopolamine patches, promethazine tablets/suppositories, meclizine)

- At the May 2019 meeting, the Committee discussed direction to build items into Statewide Drug Therapy Management Protocols for use by the ‘everyday pharmacist’. Therefore, Committee recommendations will be specific about the drugs that may be prescribed, and include the guidelines for therapy that are safe for patients. The CDC’s *Health Information for the International Traveler*, known as the Yellow Book, is the primary required source for pharmacists to use when providing travel health services.

- Committee began work on finalizing the standardized questionnaire and algorithmic patient assessment and treatment care plan process, with the assistance of subject matter experts.

- This concept, with finalized documents will be reviewed again at the next meeting, scheduled for October 25, 2019.
Committee Protocol Development (continued)

- Non-Occupational Post Exposure Prophylaxis
  - Fiona introduced the subject matter experts to the Committee and provided background information related to the non-occupational post exposure prophylaxis (n-PEP) concept.
    - SMEs: Jen Lee, Jenny Mappus, and Geoffrey L’Heureux - present
    - The SMEs provided a detailed summary of the draft protocol outline submitted, to help inform the Committee’s development of a standardized patient assessment process for a pharmacist to provide n-PEP services.
    - The Committee began work on finalizing the standardized questionnaire and algorithmic patient assessment and treatment care plan process, with the assistance of the SMEs.
    - This concept, with finalized documents, including a questionnaire, and decision-making process outlined with clear referral points and patient care follow-up requirements will be reviewed again at the next meeting, scheduled for October 25, 2019.
    - The SMEs strongly suggest additional continuing education to go along with this protocol. The Committee additionally discussed the importance of a pharmacist’s confidence in managing these sensitive patient consultations and motivational interviewing education is under consideration.

- Rules development / implementation update
  - It is anticipated that the Board will discuss edits to Division 020 rules that reflect Committee processes, expectations and compendia items at the August 8, 2019 meeting. (Note: Rules were noticed for a September 24, 2019 Rulemaking Hearing.)
  - The Committee reviewed the Statewide Protocol Draft Template as well as each of the draft for codified items. The Board will review and possibly approve these for publication at the August meeting.

- Items to explore
  - The Committee considered the two concepts received since the last meeting, Concept 2019-016 Condoms and Concept 2019-017 Female Condoms.

**Motion to recommend adding male and female condoms to the Board’s Protocol/Formulary list, following established elements, including patient assessment, notification of provider upon prescribing, and documentation, among others was made and unanimously carried (Motion by Chinn, second by Anukam).**

Upcoming Meeting Schedule – subject to change

- **Next meeting**
  - August 28, 2019 – (brief conference call to approve minutes)
  - October 25, 2019 – room 1D
  - November 20, 2019 - (brief conference call to approve minutes)
  - March 6, 2020 – room 1D

**Motion to adjourn at 3:50pm was made and unanimously carried (Motion by Burns, second by Chinn).**